By Greg Ryan
Law360, New York (October 01, 2013, 9:47 PM ET) -- A bill aimed at revamping the regulation of compounded drugs is poised to sail through Congress, but attorneys say that by allowing manufacturers to decide whether they want to be overseen by federal or state authorities, the bill fails to clear up the very confusion that prompted its creation.
The legislation, unveiled last week, comes after nearly a year of wrangling in Washington over the best way to strengthen the oversight of compoundingpharmacies in the wake of a deadly meningitis outbreak in October 2012. At...
The legislation, unveiled last week, comes after nearly a year of wrangling in Washington over the best way to strengthen the oversight of compounding
To view the full article, take a free trial now.